Niamh C.
- Country
- Ireland
- Department
- Medical Oncology
Research Overview
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
- Phase III Evaluation of Sacituzumab Govitecan Versus Physician's Choice in HER2-Negative Breast Cancer with High Relapse Risk Post-Neoadjuvant Therapy
- Efficacy and Safety of RLY-2608 Plus Fulvestrant Versus Capivasertib Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
Data & Insights
Has run more than one trial at 86 of 295 partner sites.
Specializations
Advanced Breast Cancer
The investigator specializes in treating hormone receptor-positive (HR+), HER2-negative advanced and metastatic breast cancer, exploring innovative therapeutic combinations to enhance patient outcomes. Their research encompasses novel treatment approaches for patients who have not received prior systemic anticancer treatments.
- HR-positive metastatic disease management
- First-line therapeutic strategies
- Advanced breast cancer treatment optimization
Triple Negative Breast Cancer
The investigator focuses on advancing treatment options for triple negative breast cancer, particularly in the post-surgical setting following neoadjuvant therapy. Their work involves evaluating innovative immunotherapy combinations and targeted approaches for residual invasive disease.
- Post-neoadjuvant treatment strategies
- Immunotherapy combinations
- Residual disease management
Early-Stage Breast Cancer
The investigator conducts research in primary HER2-negative breast cancer, with particular attention to high-risk patients. Their work focuses on evaluating novel therapeutic approaches for patients who have undergone standard neoadjuvant treatment and are at elevated risk of disease recurrence.
- High-risk patient management
- Post-neoadjuvant therapy optimization
- Disease recurrence prevention
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.